Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Praga Formulation in Neuropathic Pain
NCT04666714Phase 3Recruiting
- Sponsor
- EMS
- Start
- May 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pregabalin in diabetic polyneuropathy (DPN) (2 arms), sponsored by EMS. Primary endpoint: Change from baseline in pain intensity at 3 months. Started May 2023; status: recruiting.
02
Drugs
pregabalin
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT04666714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666714.